Cerus Corp (CERS)

Trade CERS now with
1/11/2021 8:49:55 AM Cerus Q4 Product Revenue $28.2 Mln, Increase Of 35% Over Last Year
11/30/2020 8:37:01 AM Cerus Announces FDA Approval For INTERCEPT Blood System For Cryoprecipitation
10/13/2020 8:36:06 AM Cerus Corporation Announces 5-Yr FDA Contract For Development Of Next Generation Pathogen Reduction Technology
8/7/2020 8:35:07 AM Cerus Says INTERCEPT Blood System Kit Shipments Surpass 7.5 Million Treatable Platelet And Plasma Doses Since Launch
7/7/2020 8:35:06 AM Cerus Announces Successful Inactivation Of SARS-CoV-2 With INTERCEPT Blood System For Plasma; Stock Up
5/26/2020 8:36:36 AM Cerus Corp Submits Pre-market Approval Supplement To FDA For Pathogen Reduced Cryoprecipitated Fibrinogen Complex
5/4/2020 8:37:03 AM Cerus Corp. Says FDA OKs Manufacture Of INTERCEPT Plasma With New Alternative Plastic Disposable Kit
4/2/2020 8:43:14 AM University Hospital, Switzerland Transfuses Two COVID-19 Patients With INTERCEPT Treated Coronavirus Convalescent Plasma
1/29/2020 9:10:12 AM Cerus Prices Public Offering Of Its Common Stock For Proceeds Of $55.0 Mln
1/23/2020 8:45:59 AM Cerus Says INTERCEPT Blood System Effective In Reducing Risk Of Transfusion-transmitted Infections
1/13/2020 8:41:31 AM Cerus Q4 Preliminary Product Revenue $20.9 Mln, Increase Of 27%
6/3/2019 8:48:08 AM Cerus Announces New Corporate Branding Campaign
1/7/2019 8:34:42 AM Cerus Expects 2019 Product Revenue Of $70 Mln To $73 Mln, Growth Of 15% To 20% Over Preliminary 2018 Results
12/19/2018 8:36:08 AM Cerus Announces First Patient Enrolled In The Phase 3 ReCePI Study
12/10/2018 8:35:50 AM American Red Cross Gets BLA Approval For INTERCEPT Platelets
10/31/2018 8:34:19 AM Cerus Receives FDA Breakthrough Device Designation For Pathogen-Reduced Cryoprecipitate
10/9/2018 4:08:01 PM Cerus Appoints Eric Bjerkholt To Board Of Directors